Liu Siyu, Sun Liyang, Yao Lanqing, Zhu Hong, Diao Yongkang, Wang Mingda, Xing Hao, Lau Wan Yee, Guan Mingcheng, Pawlik Timothy M, Shen Feng, Xu Min, Tong Xiangmin, Yang Tian
Department of Laboratory Medicine, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323050, China.
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai 200438, China.
J Clin Med. 2022 Aug 29;11(17):5075. doi: 10.3390/jcm11175075.
Background and Aim: Alpha-fetoprotein (AFP), a lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), is a protein that is induced by vitamin K deficiency or antagonist-II (PIVKA-II) that has been clinically used as a serum biomarker for early detection and diagnosis of hepatocellular carcinoma (HCC). Diagnostic performance of each serum biomarker alone, or their combinations for the detection of hepatitis C virus (HCV)-associated HCC were compared. Methods: Serum AFP, AFP-L3, and PIVKA-II levels were evaluated in patients with HCV-associated HCC, and those with chronic HCV infection without HCC (HCV-controls). The areas under the curve (AUC), sensitivity, and specificity were compared to identify the diagnostic performance of each serum HCC biomarker alone or in combination. Results: Overall, 172 HCV controls and 105 patients with HCV-associated HCC were enrolled. The AFP, AFP-L3, and PIVKA-II levels were significantly increased among patients with HCV-associated HCC when compared with HCV patients without HCC (p < 0.001). When these biomarkers were analyzed individually, PIVKA-II revealed the best predictive performance (AUC: PIVKA-II 0.90 vs. AFP 0.80 vs. AFP-L3 0.69, p < 0.001). In evaluating the combinations of any two biomarkers, the best predictive performance was found in PIVKA-II + AFP (0.93 vs. AFP + AFP-L3 0.78, p = 0.001; and PIVKA-II + AFP-L3 0.89, p < 0.001), which had no difference compared to the predictive performance of the combination of all three serum biomarkers (AFP + AFP-L3 + PIVKA-II 0.93, p = 0.277). Similar results were identified in the subgroups of patients with HCV-induced cirrhosis, and among patients with early-stage HCC defined by BCLC and TNM staging. Conclusions: The addition of the PIVKA-II test to routine AFP test maybe provide a more suitable biomarker approach to detect HCV-induced HCC in patients with HCV infection undergoing HCC surveillance.
甲胎蛋白(AFP)、AFP的刀豆球蛋白A反应性组分(AFP-L3)是一种由维生素K缺乏或拮抗剂-II(PIVKA-II)诱导产生的蛋白质,临床上已将其用作肝细胞癌(HCC)早期检测和诊断的血清生物标志物。比较了每种血清生物标志物单独或联合用于检测丙型肝炎病毒(HCV)相关HCC的诊断性能。方法:对HCV相关HCC患者以及慢性HCV感染但无HCC的患者(HCV对照)的血清AFP、AFP-L3和PIVKA-II水平进行评估。比较曲线下面积(AUC)、敏感性和特异性,以确定每种血清HCC生物标志物单独或联合使用时的诊断性能。结果:共纳入172例HCV对照和105例HCV相关HCC患者。与无HCC的HCV患者相比,HCV相关HCC患者的AFP、AFP-L3和PIVKA-II水平显著升高(p < 0.001)。单独分析这些生物标志物时,PIVKA-II显示出最佳预测性能(AUC:PIVKA-II为0.90,AFP为0.